News

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

  • Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced the implementation of an At-The-Market program (“ATM Program”) allowing the Company to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in the form of American Depositary Shares (“ADS”), each ADS representing one ordinary share, nominal value €0.01 per share, of the Company, with aggregate gross sales proceeds of up to $150,000,000 (subject to French regulatory limits and within the limits of the investors' requests expressed in the context of the program), from time to time, pursuant to the terms of an equity distribution agreement with Piper Sandler & Co. (“Piper Sandler”), acting as sales agent. The timing of any issuances in the form of ADSs will depend on a variety of factors.
    11/19/2024

Abivax presents third quarter 2024 key financial information

  • Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the quarter ended September 30, 2024.
    11/14/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Abivax SA American Depositary Shares (ABVX) can sell. Click on Rating Page for detail.

The price of Abivax SA American Depositary Shares (ABVX) is 8.28 and it was updated on 2024-12-03 09:00:38.

Currently Abivax SA American Depositary Shares (ABVX) is in undervalued.

News
    
News

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

  • Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as  Board Observer & Advisor to Abivax
    Wed, Nov. 13, 2024

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

  • Abivax Congratulates Victor Ambros and  Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in  Post-Transcriptional Gene Regulation
    Mon, Oct. 07, 2024

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

  • Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX; Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the first patient was enrolled in its Phase 2b ENHANCE-CD (NCT06456593) trial evaluating obefazimod in patients with Crohn's disease (CD).
    Thu, Oct. 03, 2024

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

  • Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
    Thu, Oct. 03, 2024

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

  • Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy and safety data at weeks 48 and 96 among week 8 induction non-responders in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC) Two moderated poster presentations highlighting corticosteroid-free efficacy and safety data of obefazimod at weeks 48 and 96 of an open-label maintenance trial, as well as the impact of obefazimod induction therapy on combined histologic and endoscopic outcomes at week 8 in patients with UC PARIS, France, September 26, 2024 – 08:30 a.m.
    Thu, Sep. 26, 2024
SEC Filings
SEC Filings
Press Releases
StockPrice Release
More Headlines
News

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

  • Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and  Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
  • 09/25/2024

Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year?

  • Here is how Abivax SA Sponsored ADR (ABVX) and PetIQ (PETQ) have performed compared to their sector so far this year.
  • 09/13/2024

Wall Street Analysts Believe Abivax SA Sponsored ADR (ABVX) Could Rally 193.62%: Here's is How to Trade

  • The mean of analysts' price targets for Abivax SA Sponsored ADR (ABVX) points to a 193.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  • 09/12/2024

Abivax presents first-half 2024 financial results

  • Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its 2024 half-year financial results, as of June 30, 2024.
  • 09/09/2024

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

  • Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the 600-patient enrollment milestone confirming ABTECT currently on pace to reach full enrollment in early Q1 2025 To date, baseline participants baseline characteristics and trial trends in line with observations from Phase 2b trial PARIS, France, August 6, 2024, 8:30 a.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today that in July 2024, the 600th participant was enrolled in the Phase 3 ABTECT Trial.
  • 08/06/2024

Abivax Provides Operational and Key Program Update

  • Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025 Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchanged Continued progress on pre-clinical combination therapy program Sylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy Officer Cash position allows for runway into Q4 2025 through ABTECT 8-week induction top-line results PARIS, France, July 15, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax”, “we” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today provided an update on the progress of key clinical and preclinical programs and its leadership and operational updates.
  • 07/15/2024

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

  • PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the “General Meeting”), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Directors of Abivax (“Board”).
  • 06/04/2024

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

  • ABIVAX Société Anonyme (OTC:AAVXF) Q4 2023 Earnings Conference Call April 8, 2024 8:30 AM ET Company Participants Patrick Malloy - SVP, IR Marc de Garidel - CEO Sheldon Sloan - Chief Medical Officer Didier Scherrer - Chief Scientific Officer Conference Call Participants Thomas Smith - Leerink Partners Vikram Purohit - Morgan Stanley Julian Harrison - BTIG Operator Ladies and gentlemen, thank you for standing by. Welcome to ABIVAX Conference Call to discuss 2023 Financial Results and Business Update.
  • 04/08/2024

Abivax reports 2023 financial results and operational update

  • Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR 223.3M initial public offering on the Nasdaq Global Market Sufficient funds to finance operations into Q4 2025, including through the announcement of top-line data from the Phase 3 ABTECT induction trials of obefazimod in ulcerative colitis (UC) Implementation of U.S. and European operational infrastructure to progress the Company's ongoing clinical and preclinical programs PARIS, France, April 2, 2024, 8:30 a.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced its 2023 annual financial results, as of December 31, 2023, and provided an update on the progress of its development programs.
  • 04/02/2024

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

  • PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis (UC), will be presented during the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) on February 21-24, 2024, in Stockholm, Sweden. "We are delighted that all four submitted abstracts have been accepted for presentations at ECCO.
  • 02/13/2024

Citi Appointed as Depositary Bank for Abivax SA's ADR Program

  • LONDON--(BUSINESS WIRE)--Citi, acting through Citibank N.A., has been appointed by Abivax SA (“Abivax”), to act as depositary bank for its initial public offering (the “IPO”) of Abivax's American Depositary Shares (“ADSs” or “ADRs”) representing its ordinary shares. Abivax's ADSs trade on the Nasdaq Global Market under the ticker symbol “ABVX”. The company's underlying ordinary shares are listed on Euronext Paris under the symbol “ABVX”. Each ADS represents one ordinary share of the company. Co.
  • 10/26/2023

Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market

  • PARIS, FRANCE / ACCESSWIRE / October 24, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the closing of its previously announced initial public offering on the Nasdaq Global Market by way of a capital increase of 20,325,500 new ordinary shares (the " New Shares "), consisting of a public offering of 18,699,460 ordinary shares in the form of American Depositary Shares (" ADSs "), each representing the right to receive one ordinary share, in the United States (the " U.S. Offering ") and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the " European Private Placement " and together with the U.S. Offering, the " Global Offering "). The offering price was set at $11.60 per ADS in the U.S. Offering and a corresponding offering price of €10.9864 per ordinary share in the European Private Placement.
  • 10/24/2023

U.S. IPO Weekly Recap: Big Launches And New Filings Keep The IPO Market Moving

  • Both the calendar and the pipeline saw some movement this past week. Two large IPOs launched, one of which also priced, and two sizable deals submitted new filings. Eight IPOs submitted initial filings, led by three sizable names. Mach Natural Resources is currently the only IPO scheduled for the week ahead, although some small issuers may join the calendar late.
  • 10/21/2023

Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris

  • PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on Euronext in Paris ("Euronext Paris") as from 4:20 p.m. CEST.
  • 10/20/2023

Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market

  • PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284:ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the pricing of its initial public offering on the Nasdaq Global Market by way of a capital increase of 20,325,500 new ordinary shares (the " New Shares "), consisting of a public offering of 18,699,460 ordinary shares in the form of American Depositary Shares (" ADSs "), each representing the right to receive one ordinary share, in the United States (the " U.S. Offering ") and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the " European Private Placement " and together with the U.S. Offering, the " Global Offering "). The offering price was set at $11.60 per ADS in the U.S. Offering and a corresponding offering price of €10.9864 per ordinary share based on an exchange rate of €1.00 = $1.0559 as published by the European Central Bank on October 19, 2023.
  • 10/20/2023

Abivax increases size of Nasdaq uplisting deal

  • Abivax S.A. ABVX, -2.53% has increased the size of its global offering to 20.33 million shares from 18.68 million shares as part of its uplisting to the Nasdaq under the ticker symbol “ABVX” from Euronext Paris, according to a filing late Wednesday.
  • 10/19/2023

Abivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price Range

  • PARIS, FRANCE / ACCESSWIRE / October 18, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the formal commencement of book-building and the filing of an amended registration statement on Form F-1, including an estimated initial public offering price range, in connection with its intention to issue, subject to market and other conditions, approximately 20,325,500 ordinary shares (including ordinary shares in the form of American Depositary Shares ("ADSs")) of the Company in an initial public offering of ADSs, each representing one ordinary share, in the United States (the "U.S. Offering") and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States (the "European Private Placement", and together, the "Global Offering"). Abivax intends to grant the underwriters (the "Underwriters") a 30-day option to purchase additional ADSs and/or ordinary shares in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in the Global Offering.
  • 10/18/2023

Abivax Readies $250 Million U.S. IPO For Drug Pipeline

  • Abivax has filed proposed terms to raise $250 million in an IPO to fund the development of its treatment candidates for chronic inflammatory diseases. The company's lead candidate, Obefazimod, is entering Phase 3 clinical trials for Ulcerative Colitis and Phase 2 trials for Crohn's Disease. The global market for treatments for ulcerative colitis is expected to reach $10.25 billion by the end of 2027, providing a significant opportunity for Abivax.
  • 10/18/2023

Abivax Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing

  • PARIS, FRANCE / ACCESSWIRE / October 16, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the start of its roadshow in connection with its intention to issue, subject to market and other conditions, 18,675,500 ordinary shares of the Company in an initial public offering of American Depositary Shares ("ADSs"), each representing one ordinary share, in the United States (the "U.S. Offering") and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States (the "European Private Placement", and together, the "Global Offering"). Abivax intends to grant the underwriters a 30-day option to purchase additional ADSs and/or ordinary shares in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in the Global Offering.
  • 10/16/2023

U.S. IPO Weekly Recap: Birkenstock Missteps In Public Debut

  • U.S. IPO Weekly Recap: Birkenstock Missteps In Public Debut
  • 10/14/2023

Abivax SA Starts U.S. IPO Process

  • Abivax SA has filed for a $100 million IPO in the U.S. to raise funds for its pipeline development plans. The company's lead candidate, Obefazimod, is entering Phase 3 clinical trials for Ulcerative Colitis and Phase 2 trials for Crohn's Disease. The global market for treatments for ulcerative colitis is expected to exceed $10 billion by 2027, driving the growth of Abivax's products.
  • 10/03/2023

Abivax reports impressive results in clinical phase 2a trial of ABX464 as an oral treatment for ulcerative colitis patients

  • PARIS--(BUSINESS WIRE)--Regulatory News: Abivax (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV, as well as treatments for inflammatory/autoimmune diseases and cancer, today announced topline results from its Phase 2a clinical trial, ABX464-101. This clinical trial was conducted in 32 patients for induction treatment of moderate-to-severe ulcerative colitis (UC), refractory to anti-TNF monoclonal antibodies or corticosteroids. In summary, the topline data indicate that ABX464 was safe, well-tolerated, and demonstrated statistically significant efficacy based on both clinical and endoscopic endpoints in this study. The mechanism of action of ABX464 is triggered by an increased expression of miR124, which is a potent anti-inflammatory microRNA. The final 8-week top-line data from this study are as follows: The difference between ABX464 and placebo in colorectal mucosal healing was statistically significant (p2.7 million globally. Pharmaceutical sales for this disease in the major global markets3 are estimated to be around $5.5 billion in 2017. For IBD (inflammatory bowel disease), which includes both ulcerative colitis and Crohn’s disease, the sales in the major global markets are estimated to be around $ 15 Billion for the same period. The financial potential of treatments in the anti-inflammatory space are exemplified by anti-TNF monoclonal antibodies (Humira, Remicade, Simponi) with estimated global annual sales of > $30 billion, including at least $2.5 billion for ulcerative colitis4. “These impressive clinical trial data are indicative of the potential for ABX464’s unique mechanism of action to safely and effectively bring substantial clinical benefit to patients who are not adequately helped by currently available therapeutics and are struggling from the devastating consequences of this inflammatory disease,” said Prof. Dr. Hartmut Ehrlich, M.D., Chief Executive Officer at Abivax. “Based on these exciting results, Abivax will initiate, without delay, a phase 2b dose-ranging study in Europe, with potential input from US KOLs and FDA on study design. Furthermore, these data strongly encourage us to pursue phase 2 clinical trials in other inflammatory indications including Crohn’s disease.” A detailed presentation of these top line results will be run by the Management of ABIVAX during a conference call from 4 to 5 p.m. CEST/10 to 11 am ET on Tuesday, September 4th, 2018 (phone number table appended). About ABX464 Inflammation is a cornerstone of inflammatory bowel disease (IBD), more specifically in ulcerative colitis and Crohn’s disease. When evaluated in a mouse model of IBD, ABX464 demonstrated a long-lasting effect in preventing the typical symptoms of inflammatory colitis, including histological improvements5. A ten-fold increase of miR124, a micro-RNA with potent anti-inflammatory properties in peripheral blood mononuclear cells (PBMCs) was observed. ABX464 was shown to target the cap binding complex (CBC), which is a novel mechanism of action for anti-inflammatory drugs. By ABX464 binding to the CBC, it reinforces the biological functions of this complex in cellular RNA biogenesis including splicing. Therefore, the molecule acts inside injured immune cells to preserve the integrity of newly synthesized RNA. ABX464 enhanced the expression and splicing of a single long non coding RNA to generate the anti-inflammatory miR-124. This work was conducted by the cooperative laboratory between Abivax and the CNRS (Centre National de Recherche Scientifique) in Montpellier, France, headed by Prof. Jamal Tazi. WEBCAST PRESENTATION Abivax senior management will host a webcast and teleconference today at 4:00 pm CET (Paris time) / 10am ET (NYC time), to discuss these clinical results and address questions. Attendees can participate using the following coordinates: Confirmation code : 1766735 To access the presentation: https://edge.media-server.com/m6/p/w9fv6njz The UK local number +44 330 336 9411 should be used as International Dial in number About ABIVAX (www.abivax.com) ABIVAX is mobilizing the body’s natural immune machinery to treat patients with viral infections, autoimmune diseases and cancer. A clinical-stage company, ABIVAX leverages its antiviral and immune enhancing platforms to optimize candidates to cure HIV and treat inflammatory bowel diseases, as well as liver cancer. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). More information on the company is available at www.abivax.com/en. Follow us on Twitter @ABIVAX_ 1 Company estimate based on GlobalData 2 The partial Mayo Score is composed of stool frequency, rectal bleedings and the physician’s global assessment.of disease severity. 3 The total Mayo score is composed of the 3 parameters listed above, plus mucosal appearance at endoscopy 4 US, Germany, France, Uk, Spain, Italy, Japan 5 Source: Global Data (2017) 6 K Chebli et al., The Anti-HIV Candidate ABX464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages. Nature Scientific Reports 2017, DOI:10.1038/s41598-017-04071-3 DISCLAIMER This press release contains forward-looking statements, forecasts and estimates with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document de Référence). Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. ABIVAX disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.
  • 09/04/2018

Analysis of Ongoing ABX203 Phase IIb/III Trial in Chronic Hepatitis B Virus Infection Shows Good Safety, but Primary Endpoint of Study is Unlikely to Be Reached

  • PARIS--(BUSINESS WIRE)--Regulatory News: ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an innovative company developing anti-viral therapies and immunotherapeutics for infectious diseases like HIV/AIDS, chronic hepatitis B (CHB), chikungunya, ebola as well as an adjuvant to enhance the immune response, today announced that a futility analysis on the primary end-point of its ABX203-002 trial, a Phase IIb/III trial of ABX203 in CHB patients, determined that the trial is unlikely to reach its primary endpoint. The ABX203-002 study is an open-label, randomized, comparative study designed to assess the efficacy of ABX203 to maintain control of the hepatitis B virus after cessation of nucleotide analogs (NUCs), in particular in controlling viral load for a much longer period of time when compared to current treatment options. This study is ongoing in seven Asian/Pacific countries (Taiwan, Hong-Kong, Thailand, Singapore, South Korea, Australia and New-Zealand). In this large scale controlled and randomized study, where 276 subjects were enrolled as of September 2015, one group of patients received ABX203 for 24 weeks, in addition to the current standard of care (nucleoside analogues, NUCs). All therapy was stopped after 24 weeks, and these patients are evaluated against a control group receiving NUCs only. The study’s primary efficacy endpoint is the percentage of subjects with viral load <40 IU/mL at week 48, i.e 24 weeks after the treatment with ABX203 has been completed. An unscheduled futility analysis was initiated because of a recent increase in the patients’ drop out rate related to viral escape. A futility analysis is conducted during an ongoing clinical trial to describe the probability of a study to reach its primary endpoint. The result of this analysis shows that a positive outcome of the study regarding its primary endpoint is unlikely. The Data Safety and Monitoring Board (DSMB) of study ABX203-002 was convened. The DSMB has recognized the good safety profile of ABX203 and recommended that the study should continue as per protocol, to monitor patients 24 weeks post-treatment in order to continue to assess their viral load and to have a comprehensive view of the secondary endpoints. Investigators, health authorities and patients are being informed of the conclusions of the DSMB. In a previous Phase II study, with a different design and carried out in Asia, treatment-naïve patients with chronic hepatitis B were administered ABX203 as monotherapy. That study established a significantly longer period to viral rebound as compared to patients receiving Peg-Interferon Alpha. The future development of ABX203 is under review, including the usefulness of an adjuvant boosting the response to this immunotherapy, as well as new administration schedules and therapeutic combinations that may be evaluated via other preclinical and, potentially, clinical testing. The ABIVAX portfolio includes other product candidates that are progressing to plan. ABX464, which is in development for the treatment of HIV, recently started a second Phase IIa trial after demonstrating its safety and anti-viral properties in the first Phase IIa study earlier this year. The ongoing placebo controlled Phase IIa study ABX464-004 is designed to demonstrate the long-lasting effect of ABX464, which has been observed in preclinical studies. The study is enrolling 28 patients whose HIV infection is already fully controlled by boosted Darunavir; 21 of the patients will be administered ABX464, and seven will receive placebo in addition to their current antiretroviral therapy. After 28 days, all treatment will be discontinued and the primary endpoint will compare the time elapsed until the HIV viral load rebounds in the ABX464-treated patients and the placebo control group. The primary efficacy endpoint measures time to rebound of the viral load. Such rebound is believed to originate from the HIV reservoirs, which are not affected by current combination antiretroviral treatments. Preliminary results of this study are expected in Q4 2016. ABIVAX is leveraging three distinct drug discovery platforms, outlined below: 1) A unique and proprietary anti-viral discovery platform, which ABIVAX used to identify ABX464. ABIVAX also is currently optimizing two small molecule therapeutic candidates, discovered using the platform, which have potential for treatment of chikungunya. Additionally, the anti-viral discovery platform is currently being used to generate additional new chemical entities to treat dengue, RSV and other infectious diseases. 2) An adjuvant discovery platform, used to identify lead adjuvant ABX196, an immune enhancer for infectious diseases and oncology. 3) A hyperimmune platform, currently focused on discovering a novel approach to treating Ebola. Further details regarding these discovery platforms and the exciting molecules that they have produced will be communicated in an R&D day during the second half of this year. ABIVAX senior management will host a conference call to discuss these developments today at 7PM CET/1PM EDT. Following are the dial-in details. From France: +33 (0)1 76 77 22 31From Germany: +49 (0)69 2222 10626From the United Kingdom: +44 (0)203 427 1916From the United States: +1 212 444 0895 Pass code: 8743808 A replay of the conference call will be available for seven days by dialing the following numbers: France: +33 (0)1 74 20 28 00Germany: +49 (0)89 2030 3201United Kingdom: +44 (0)20 3427 0598United States: +1 347 366 9565 Replay Passcode: 8743808 ABIVAX is an innovative biotechnology company in the discovery and development of anti-viral therapeutics and immunotherapeutics to treat some of the world’s most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, an immunotherapy recently approved in Cuba and in late-stage clinical development in other countries that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and immunotherapeutics that may enter the clinical stage in the coming 18 months. A recently updated corporate presentation, which includes a timeline for the company’s anticipated news flow, is available at www.abivax.com. Follow us on Twitter @ABIVAX
  • 06/17/2016
Unlock
ABVX Ratings Summary
ABVX Quant Ranking